Haosi Bio Enters Strategic Partnership with China Jinmao and Beike Jian Group to Advance Clinical Mass Spectrometry Ecosystem

Recently, Haosi Biotech, China Jinmao (HK.00817), and Beikejian Group reached a consensus and formally signed a strategic cooperation agreement after more than two months of mutual due diligence, continuous negotiations, and frequent meetings. The parties agreed on collaborating in areas such as the integration of industry and finance, expansion of industrial real estate projects, scientific upgrading of government industrial parks, promotion of the commercialization of corporate scientific research achievements, and joint advancement of regional health industries. Through this strategic partnership, each party will leverage its respective industrial and resource advantages. On one hand, this will accelerate the development and nationwide layout of Haosi Biotech’s full-platform mass spectrometry business, promoting the creation of an industry-leading clinical mass spectrometry ecosystem. On the other hand, through collaborative development across various domestic industrial parks, the partnership will adopt a point-to-area approach. By embedding a precision medicine industry chain supported by the mass spectrometry ecosystem, the collaboration will enhance the distinctive features of the science parks under China Jinmao and Beikejian Group, achieving a win-win outcome for all three parties.

Haosi Bio is a high-tech enterprise that provides a variety of clinical mass spectrometry testing products and services based on tandem mass spectrometry platforms. The company has independently developed a series of mass spectrometry testing products, including innovative early screening and diagnostic products for major diseases such as Alzheimer's disease, cardiovascular diseases, and urinary system diseases. It focuses on creating China's leading complete solutions for mass spectrometry testing that are closely aligned with clinical practice. Its business covers the entire industry chain, with layouts in reagent research and development and production, medical inspection centers, and domestically produced equipment. Under the leadership of a team with an industry-leading scientific research background, Haosi Bio has developed rapidly, with rapid revenue growth. In just five years, Haosi Bio has achieved a transformation from following to running alongside and gradually taking the lead in China's mass spectrometry testing industry.

As leading domestic urban operators and technology-focused real estate developers, China Jinmao and Beikejian Group will leverage their industrial resources to support Haosi Bio, a portfolio company, in building an international mass spectrometry industrial park and a clinical mass spectrometry testing center. Furthermore, they will introduce both consumer-facing (C-end) and business-facing (B-end) users to Haosi Bio through real-world scenarios such as residential communities, commercial complexes, and hotels. In the future, close collaboration between Haosi Bio, China Jinmao, and Beikejian Group will drive the diversification of the company’s business, pioneer innovative application areas, and establish a first-class domestic clinical mass spectrometry industry ecosystem.

Wang Jia, Head of Healthcare Industry Investment at Jinmao CapitalIt is indicated that clinical mass spectrometry will become the next multi-billion yuan blue-ocean sector in clinical diagnostics, with enormous growth potential. Haosi Biology’s R&D strength and product commercialization capabilities are at the forefront of the clinical mass spectrometry field, and its innovative products for early diagnosis of Alzheimer’s disease, prostate cancer detection, and cardiovascular disease testing have achieved internationally leading performance. Jinmao Capital will leverage China Jinmao’s industrial layout to support Haosi Biology’s business expansion across China, and jointly promote the development of China Jinmao’s healthy living ecosystem.

Gao Jiaqing, Deputy General Manager of Beikejian GroupIt was stated that Haosi Biotechnology has independently developed a series of clinical mass spectrometry testing products that are leading in China and even globally, and has integrated the upstream and downstream segments of the industrial chain to build an integrated clinical mass spectrometry testing platform. Leveraging its extensive experience in park operation, enterprise incubation, industrial services, and its industrial resources, Beikejian Group will support Haosi Biotechnology in better applying mass spectrometry solutions to clinical practice, thereby making greater contributions to precision medicine in China.

Li Lin, Founder of Haosi BiologyStatement: Haosi Biology aims to extend its mass spectrometry-based professional testing and reagent kit supply services across China within the next three years. In accordance with the company’s strategic plan, we will establish at least six regional testing centers and R&D institutions with diverse functional capabilities. Particularly in the context of a market where epidemic prevention has become normalized, a well-structured layout is essential to meet the demand for high-quality, localized regional services. The participation of China Jinmao and Beike Jian Group comes as a timely boost. Their presence in 53 mature industrial parks nationwide, coupled with comprehensive investment promotion and implementation support policies, will accelerate the deployment of our national medical testing centers and R&D facilities. Leveraging the two groups’ extensive experience in industrial commercialization and their channel resources will facilitate the translation of our scientific achievements into practical applications, while also attracting more B-end and C-end users and expanding the application scenarios for mass spectrometry. We hope this strategic partnership will drive the diversification of Haosi’s business operations. We will continue to uphold our philosophy of “Making Mass Spectrometry Simple” and work diligently with our partners to make the greatest possible contribution to the rise of in vitro diagnostics based on mass spectrometry in China.

China Jinmao is the platform enterprise for the real estate and hotel segments under Sinochem Holdings, a key state-owned backbone enterprise. With the mission of “unleashing the future vitality of cities,” China Jinmao consistently adheres to a high-end positioning and premium quality strategy. Centered on its “Two Wheels, Two Wings” strategy and focusing on the “Two Drivers, Two Upgrades” model, the company is committed to becoming a leading urban operator in China. To date, it has established a stable presence in 53 core cities, successfully secured more than 30 urban operation projects, and built a portfolio of high-end product series centered on the “Jinmao” brand.

As the equity investment platform of China Jinmao, Jinmao Capital focuses on private equity investments in the big health and advanced technology sectors. Leveraging China Jinmao’s urban operation development strategy, it conducts value-driven investments grounded in real-world scenarios and tangible carriers, empowering the creation of healthy urban ecosystems through capital. Its healthcare investment portfolio covers niche segments such as high-end medical devices, precision diagnostics, and smart healthcare.

Beijing Science and Technology Construction Group (BKC) is a pioneering enterprise in China, established as the earliest leader specializing in technology-oriented real estate with a focus on the development and operation of science parks and technology new towns. It has successfully developed more than ten branded parks, including the Zhongguancun Core Business District, Zhongguancun Software Park, Zhongguancun Life Science Park, and Daxing Biomedical Base. As the venture capital fund management platform under BKC, Kehui Venture Capital is committed to identifying and nurturing competitive leading enterprises in fields such as new materials, artificial intelligence, healthcare, and big data.